About IMNN-001 Immunotherapy Designed using IMUNON's proprietary TheraPlas® platform technology, IMNN-001 is an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables ...

IMNN-001, based on the company’s proprietary TheraPlas® technology platform, is an interleukin-12 (IL-12) DNA plasmid vector encased in a nanoparticle delivery ... 001 in an oral presentation ...

"We are happy with the opportunity to present data from the Phase 2 dose expansion cohort of DSP107 in combination with a PD1/PD-L1 checkpoint inhibitor in an oral presentation at ASCO's Annual ...

BOSTON--(BUSINESS WIRE)--nChroma Bio (“nChroma”), a genetic medicines company advancing programmable in vivo delivery to overcome ... one for oral presentation and two for poster presentations ...

“We are particularly excited to be presenting, in the prestigious Presidential Symposium, our potent combination of epigenetic regulation and capsid delivery capabilities as an anticipated one ...

SAN DIEGO -- The oral full-spectrum microbiome drug EBX-102-02 was well ... and there's a lack of a standardized delivery method, he said. EBX-102-02 is derived from screened human stool donations and ...

Numerous approaches have been or are being evaluated for optimal oral delivery, including live vectors, various particulate formulations, mucosal adjuvants and transgenic plants. Recent progress ...

All students in the oral presentation must submit at least one slide to accompany their presentation. All presentation slides must be submitted in PowerPoint (PPT) format. Slides should not include ...

Merck & Co.'s peptides could be undergoing a transformation into oral tablets thanks to a $493 million licensing deal the company inked with Austria-based drug delivery technology maker Cyprumed.

Results are being highlighted in an oral presentation at the 2025 American ... an IL-12 DNA plasmid vector encased in a nanoparticle delivery system that enables cell transfection followed by ...